These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30667544)

  • 21. Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.
    Shimamura T; Kubota N; Nagasaka S; Suzuki T; Mukai H; Shibuya K
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3150-5. PubMed ID: 21555762
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Kubota-Ishida N; Takei-Masuda N; Kaneda K; Nagira Y; Chikada T; Nomoto M; Tabata Y; Takahata S; Maebashi K; Hui X; Maibach HI
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
    Bohn M; Kraemer KT
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of Antifungal Activity and Nail Penetration of ME1111, a New Antifungal Agent for Topical Treatment of Onychomycosis.
    Tabata Y; Takei-Masuda N; Kubota N; Takahata S; Ohyama M; Kaneda K; Iida M; Maebashi K
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1035-9. PubMed ID: 26643333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.
    Baran R; Sigurgeirsson B; de Berker D; Kaufmann R; Lecha M; Faergemann J; Kerrouche N; Sidou F
    Br J Dermatol; 2007 Jul; 157(1):149-57. PubMed ID: 17553051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
    Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
    Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetics of amorolfine in human nails.
    Polak A
    Mycoses; 1993; 36(3-4):101-3. PubMed ID: 8366874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antifungal activity, experimental infections and nail permeation of an innovative ciclopirox nail lacquer based on a water-soluble biopolymer.
    Togni G; Mailland F
    J Drugs Dermatol; 2010 May; 9(5):525-30. PubMed ID: 20480796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absorption of amorolfine through human nail.
    Franz TJ
    Dermatology; 1992; 184 Suppl 1():18-20. PubMed ID: 1550966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ex vivo nail infection as an effective preclinical method for screening of new topical antifungals.
    Quatrin PM; Kaminski TFA; Berlitz SJ; Guerreiro ICK; Canto RFS; Fuentefria AM
    J Mycol Med; 2020 Jun; 30(2):100938. PubMed ID: 32111505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection.
    Schaller M; Borelli C; Berger U; Walker B; Schmidt S; Weindl G; Jäckel A
    Med Mycol; 2009 Nov; 47(7):753-8. PubMed ID: 19888808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
    Gupta AK; Fleckman P; Baran R
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential of Naftifine Application for Transungual Delivery.
    Šveikauskaitė I; Briedis V
    Molecules; 2020 Jul; 25(13):. PubMed ID: 32635240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of the subungual antifungal activity of amorolfine after 1 month's treatment in patients with onychomycosis: comparison of two nail lacquer formulations.
    Mensing H; Polak-Wyss A; Splanemann V
    Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():29-32. PubMed ID: 1458661
    [No Abstract]   [Full Text] [Related]  

  • 35. Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum.
    Monti D; Mazzantini D; Tampucci S; Vecchione A; Celandroni F; Burgalassi S; Ghelardi E
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis.
    Tabara K; Szewczyk AE; Bienias W; Wojciechowska A; Pastuszka M; Oszukowska M; Kaszuba A
    Postepy Dermatol Alergol; 2015 Feb; 32(1):40-5. PubMed ID: 25821426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of amorolfine or ciclopirox in combination with terbinafine against pathogenic fungi in onychomycosis-Results of an in vitro investigation.
    Schaller M; Walker B; Nabhani S; Odon A; Riel S; Jäckel A
    Mycoses; 2024 Mar; 67(3):e13710. PubMed ID: 38414346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
    Gupta AK
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vitro Nail Penetration and Antifungal Activity of Tavaborole, a Boron-Based Pharmaceutical.
    Coronado D; Merchant T; Chanda S; Zane LT
    J Drugs Dermatol; 2015 Jun; 14(6):609-14. PubMed ID: 26091387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The dermatopharmacologic profile of ciclopirox 8% nail lacquer.
    Bohn M; Kraemer K
    J Am Podiatr Med Assoc; 2000; 90(10):491-4. PubMed ID: 11107709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.